ProQR Therapeutics N.V. (PRQR)

Market Cap	244.31M
Revenue (ttm)	4.23M
Net Income (ttm)	-77.42M
Shares Out	71.43M
EPS (ttm)	-1.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	706,471
Open	3.45
Previous Close	3.46
Day's Range	3.26 - 3.47
52-Week Range	0.53 - 3.85
Beta	0.12
Analysts	Buy
Price Target	3.28 (-4.09%)
Earnings Date	Mar 30, 2023

About PRQR

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Rad...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 18, 2014
• Employees: 181
• Stock Exchange: NASDAQ
• Ticker Symbol: PRQR

Financial Performance

In 2021, PRQR's revenue was 2.40 million, a decrease of -74.64% compared to the previous year's 9.45 million. Losses were -61.62 million, 32.3% more than in 2020.

Financial numbers in EUR

Analyst Forecast

According to 14 analysts, the average rating for PRQR stock is "Buy." The 12-month stock price forecast is $3.28, which is a decrease of -4.09% from the latest price.

Price Target

$3.28

(-4.09% downside)

Analyst Consensus: Buy